Diferencia entre revisiones de «Template:Endocarditis Empiric Antibiotics»

(Add pediatric empiric dosing section)
 
(No se muestran 3 ediciones intermedias de otro usuario)
Línea 15: Línea 15:
{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}
{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}


===Miscellaneous===
===Pediatric Empiric===
*No therapeutic anticoagulation necessary
*{{AntibioticDose|disease=Endocarditis|drug=Vancomycin|dose=15mg/kg IV q6hrs (max 2g/dose)|context=Pediatric Empiric|population=Pediatric}} + {{AntibioticDose|disease=Endocarditis|drug=Gentamicin|dose=1mg/kg IV q8hrs|context=Pediatric Empiric|population=Pediatric}}
**Anticoagulation carries higher risk of bleeding without reducing embolic complication or mortality benefit<ref>Elkaryoni A et al. ANTICOAGULATION IN INFECTIVE ENDOCARDITIS: INSIGHTS FROM NATIONWIDE INPATIENT SAMPLE. Journal of the American College of Cardiology. Volume 73, Issue 9 Supplement 1, March 2019.</ref>
*{{AntibioticDose|disease=Endocarditis|drug=Nafcillin|dose=50mg/kg IV q6hrs (max 2g/dose)|context=Pediatric MSSA|population=Pediatric}} if MSSA confirmed
*[[Septic pulmonary embolism]]
*{{AntibioticDose|disease=Endocarditis|drug=Ceftriaxone|dose=100mg/kg/day IV divided q12h (max 4g/day)|context=Pediatric Empiric|population=Pediatric}} as alternative
**Most common culture growths were MSSA, MRSA, and candida
**Furthermore, therapeutic anticoagulation not indicated for [septic pulmonary embolism]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>
 
===Miscellaneous===
*No therapeutic anticoagulation necessary
**Anticoagulation carries higher risk of bleeding without reducing embolic complication or mortality benefit<ref>Elkaryoni A et al. ANTICOAGULATION IN INFECTIVE ENDOCARDITIS: INSIGHTS FROM NATIONWIDE INPATIENT SAMPLE. Journal of the American College of Cardiology. Volume 73, Issue 9 Supplement 1, March 2019.</ref>
*[Septic pulmonary embolism]
**Most common culture growths were MSSA, MRSA, and candida
**Furthermore, therapeutic anticoagulation not indicated for [septic pulmonary embolism]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>

Revisión actual - 13:03 20 mar 2026

Native Valves

Options:[1]

Suspected MRSA:[1]

Prosthetic Valves (Early)

Early prosthetic valve endocarditis defined as < 12 months post surgery[1]

IV Drug User without Prosthetic Valve

Prosthetic Valve (Late)

Late prosthetic valve endocarditis defined as ≥ 12 months post surgery[1]
  • Same as native valve endocarditis empiric therapy

Dental Procedure Prophylaxis

All antibiotics options are given as a single dose 1 hour prior to the dental procedure

Options:[2]

Pediatric Dosing:

Pediatric Empiric

  1. 1.0 1.1 1.2 1.3 ESC Task Force Guidelines on the prevention, diagnosis, and treatment of infective endocarditis. European Heart Journal (2009) 30, 2369–2413 doi:10.1093/eurheartj/ehp285 PDF
  2. AHA Pocket Card Dental Prophylaxis Endocarditis